Whitepapers
Application Highlight: A Highly Selective Method for the Analysis of Drospirenone in Human Plasma
Several common birth control formulations contain both drospirenone and ethinyl estradio. A highly selective and sensitive analytical method for the analysis of drospirenone in human plasma has been developed for use in bioequivalence studies.
ChiroTouch Brings Focus on a 'True Wellness Model' for Practices with Release of Latest White Paper
ChiroTouch Brings Focus on a 'True Wellness Model' for Practices with Release of Latest White Paper. In addition to its recent webinar series on helping chiropractors create a wellness center, ChiroTouch™ recently published "True Wellness Model", a white paper authored by Dr. Angie Meyer and Dr.
TTR02 and PCS02 Formulation Lock
Pre-clinical Development of ALN-TTR RNAi Therapeutic for Treatment Of Transthyretin-mediated Amyloidosis Peripheral Nerve Society June 29, 2011 Transthyretin (TTR)-Mediated Amyloidosis (ATTR) Program Unmet Need and Product Opportunity RNAi to treat genetic disease ATTR is significant orphan disease
Microsoft Word - SBI Final White Paper final version for posting 6-18-11 _2_.doc
Breast implants are medical devices that are used to augment breast size or to reconstruct the breast following mastectomy or to correct a congenital abnormality. Breast implants consist of a silicone outer shell and a filler (most commonly silicone gel..
JP Morgan Healthcare Conference
Alnylam RNAi Roundtable May 13, 2011 Agenda & Introductions Welcome Cynthia Clayton » Senior Director, Investor Relations and Corporate Communications Program Overview Akshay Vaishnaw, M.D., Ph.D. (Moderator) » Senior Vice President, Clinical Research Jared Gollob, M.D. » Senior Director, Clinical
2011 Alnylam Template
Serial measurements of Circulating TTR in Subjects with TTR Amyloidosis or Carriers of Mutant TTR Peripheral Nerve Society June 2011 Transthyretin (TTR) Amyloidosis (ATTR) Background Autosomal dominant disease Caused by extracellular deposition of mutant and wild-type TTR in target organs such as
Slide 1
ALN-VSP02 Phase 1 Trial Update Demonstrating RNAi in Man Jared A. Gollob, M.D. January 4, 2011 Dana-Farber Cancer Institute Agenda LNPs and ALN-VSP02: Background Phase 1 Trial Safety Data Pharmacodynamic Data » 5’ RACE » DCE-MRI Summary 2 Lipid Nanoparticles for Systemic Delivery 3 Liver Targeting
RNAi Therapeutics Targeting PCSK9 for LDLc Lowering in Hypercholesterolemia M. D. Frank-Kamenetsky1...
RNAi Therapeutics Targeting PCSK9 for LDLc Lowering in Hypercholesterolemia M. D. Frank-Kamenetsky1 , T. Racie1 , A. Akinc1 , N. Anderson2 , L. Nechev1 , S. Shulga-Morskaya1 , K. Mills1 , S. Millstein1 , T. Lei1 , R. Duncan1 , A. Grefhorst2 , G. Wang1 , R. Kallanthottathil1 , M. Maier1 , S. Semple3
Page:
Refine by Topic:
Refine by Content Type:
Refine by Source:
- www.alnylam.com (5)
- www.dddmag.com (1)
- www.fda.gov (1)
- www.prlog.org (1)
